Preclinical tests show promise against primary effusion lymphoma

06/27/2013 | InfectionControlToday.com

A study in the journal Oncogene found that a class of drugs called BET bromodomain inhibitors can effectively treat primary effusion lymphoma, a rare and aggressive blood cancer. The disease is caused by infection with Kaposi's sarcoma-associated herpes virus and is most commonly seen among patients with HIV. Inhibitors targeting the BRD4 protein halted the growth of PEL cells in laboratory and animal tests.

View Full Article in:

InfectionControlToday.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ